HIKMA PHARMACEUTICALS (HIK) – Healthcare
| Price: £14.95 -1.4% | P/E: 10.5x |
| Market Cap: £4.45bn | Yield: 4% |
A month after the firm lowered its outlook, Hikma chief executive Riad Mishlawi is out the door and chairman Said Darwazah is stepping back in while the company looks for a new candidate.
Group guidance remains unchanged from the 6 November trading update and the full-year results will be released on 26 February 2026.
Our View
With the shares down around 25% year-to-date and sitting at their lowest since late 2023, it was inevitable something would have to give and in time-honoured tradition the chief executive has fallen on his sword.
Hikma is another stock we need to look into from a valuation perspective, so we’ll reprise once we’ve done the legwork.
Read the press release here:
https://www.hikma.com/investors
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
